top of page
Gossamer Bio, Inc. (NASDAQ: GOSS)
Lifshitz Law PLLC is investigating possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: while publicly touting overwhelmingly positive results to investors, the Company concealed material adverse facts regarding the design of the Gossamer’s Phase 3 PROSERA study, including their failure to adequately control for placebo response at the Latin American testing sites.
If you are a GOSS investor, and would like additional information about our investigation, please complete the Information Request Form.
bottom of page